Literature DB >> 16391431

Nonhuman primate models of intrauterine cytomegalovirus infection.

Peter A Barry1, Kristen M Lockridge, Shariar Salamat, Steven P Tinling, Yujuan Yue, Shan Shan Zhou, Sidney M Gospe, William J Britt, Alice F Tarantal.   

Abstract

Congenital human cytomegalovirus (HCMV) infection has long been recognized as a threat to the developing fetus, even though studies have shown that only a subset of congenital infections results in clinical signs of disease. Among the estimated 8000 children who develop sequelae from congenital CMV infection each year in the United States alone, most suffer permanent developmental defects within the central nervous system. Because there is currently no approved vaccine for HCMV, and anti-HCMV drugs are not administered to gravid women with congenital infection because of potential toxicity to the fetus, there is a clear clinical need for effective strategies that minimize infection in the mother, transplacental transmission of the virus, and/or fetal disease. Animal models provide a method to understand the mechanisms of HCMV persistence and pathogenesis, and allow for testing of novel strategies that limit prenatal infection and disease. The rhesus macaque model is especially well suited for these tasks because monkeys and humans share strong developmental, immunological, anatomical, and biochemical similarities due to their close phylogenetic relationship. This nonhuman primate model provides an invaluable system to accelerate the clinical development of promising new therapies for the treatment of human disease. This review addresses salient findings with the macaque model as they relate to HCMV infection and potential avenues of discovery, including studies of intrauterine CMV infection. The complexity of the natural history of HCMV is discussed, along with the ethical and logistical issues associated with studies during pregnancy, the recent contributions of animal research in this field of study, and future prospects for increasing our understanding of immunity against HCMV disease.

Entities:  

Mesh:

Year:  2006        PMID: 16391431     DOI: 10.1093/ilar.47.1.49

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  43 in total

1.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

2.  Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.

Authors:  A McGregor; K Y Choi; M R Schleiss
Journal:  Virology       Date:  2010-11-20       Impact factor: 3.616

Review 3.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

Review 4.  Fate-Regulating Circuits in Viruses: From Discovery to New Therapy Targets.

Authors:  Anand Pai; Leor S Weinberger
Journal:  Annu Rev Virol       Date:  2017-08-11       Impact factor: 10.431

Review 5.  Macaque monkeys in Zika virus research: 1947-present.

Authors:  Christina Newman; Thomas C Friedrich; David H O'Connor
Journal:  Curr Opin Virol       Date:  2017-07-24       Impact factor: 7.090

6.  Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.

Authors:  Thomas J Conlon; Cathryn S Mah; Christina A Pacak; Mary B Rucker Henninger; Kirsten E Erger; Marda L Jorgensen; C Chang I Lee; Alice F Tarantal; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2016-12       Impact factor: 5.032

Review 7.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

Review 8.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

9.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

10.  Antagonism of the protein kinase R pathway by the guinea pig cytomegalovirus US22-family gene gp145.

Authors:  Craig J Bierle; Mark R Schleiss; Adam P Geballe
Journal:  Virology       Date:  2012-08-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.